Recently, encouraging phase II data were presented on the ICI–TKI combination of lenvatinib plus tislelizumab (PD-1 antibody) in FH-deficient RCC tumors, which showed an ORR of 93.3% (14/15 patients), including CRs in 3 of 15 patients (20%) [79]. The gene discussed is FH; the disease is renal cell adenocarcinoma.